8th Eurasian Hematology Oncology Summit

 

8th Eurasian Hematology Oncology Summit
Avatar

Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in 2021: Induction & Standard (VCD, VTD, VRd, Dara-VTD), Upfront ASCT vs. Bortezomib, Len Maintenance Until Progression

By 8th Eurasian Hematology Oncology Summit FEATURING Angelo Maiolino
By 8th Eurasian Hematology Oncology Summit FEATURING Angelo Maiolino
0 views
May 13, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Videos
14:53
8th Eurasian Hematology Oncology Summit

Maintenance Therapy in AML: Overview of Outcomes and Future Approach…

Feat. T. Kadia
13:09
8th Eurasian Hematology Oncology Summit

Brentuximab Vedotin in HL: Evaluating the Clinical Data

Feat. C. Gisselbrecht
10:10
8th Eurasian Hematology Oncology Summit

The Role of MRD in AML: Navigating Testing Techniques & Predicti…

Feat. T. Kadia
19:17
8th Eurasian Hematology Oncology Summit

Treating Myelofibrosis in 2021: What Are the Efficacy Data for Ruxol…

Feat. H. Kathrin Al-Ali
19:08
8th Eurasian Hematology Oncology Summit

2021 Efficacy Data Review in Relapsed CLL: BTK Inhibitors, Ven+/-Rit…

Feat. S. O'Brien
16:00
8th Eurasian Hematology Oncology Summit

Frontline Treatment of CLL: Surveying Outcomes With BTKi / BCL-2i Op…

Feat. S. O'Brien
09:15
8th Eurasian Hematology Oncology Summit

How I Treat ET in 2021: WHO True-ET, Thromboembolic/Bleeding Complic…

Feat. D. Wolf
10:04
8th Eurasian Hematology Oncology Summit

How I Treat PV in 2021: JAKi in Symptomatic Disease, Anti-Clonal Act…

Feat. D. Wolf
14:23
8th Eurasian Hematology Oncology Summit

Surveying the Data on DLBCL Treatments: RT Therapy in the PET Era, I…

Feat. U. Vitolo
05:47
8th Eurasian Hematology Oncology Summit

R/R DLBCL: Novel Strategies in 1L/2L Treatment

Feat. U. Vitolo
06:03
8th Eurasian Hematology Oncology Summit

Novel Strategies in 1/2L Large Cell Lymphoma: Navigating Treatment O…

Feat. U. Vitolo
07:18
8th Eurasian Hematology Oncology Summit

How Important Is Imaging (PET) for 1L Early Stage HL?

Feat. C. Gisselbrecht
21:14
8th Eurasian Hematology Oncology Summit

2021 Treatment Considerations for Follicular Lymphoma: Localized, Ad…

Feat. G. Gaidano
12:00
8th Eurasian Hematology Oncology Summit

Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in…

Feat. A. Maiolino
07:11
8th Eurasian Hematology Oncology Summit

Survival Data for Newly Diagnosed ASCT-Ineligible MM: VRd vs. Rd, VM…

Feat. A. Maiolino
21:36
8th Eurasian Hematology Oncology Summit

CAR-T Cell Therapy for Multiple Myeloma

Feat. E. Terpos
07:00
8th Eurasian Hematology Oncology Summit

MRD in CLL: What Were the Changes and Issues Over the Years? Is This…

Feat. R. Foa
17:18
8th Eurasian Hematology Oncology Summit

2021 Updates on MRD in CLL: Chemoimmunotherapy vs. Targeted Approach…

Feat. R. Foa
06:59
8th Eurasian Hematology Oncology Summit

2021 Oral HMAs Efficacy Data in MDS: Decitabine + Cedazuridine for H…

Feat. G. Garcia-Manero
15:42
8th Eurasian Hematology Oncology Summit

2021 MDS Highlights: Luspatercept for Very Low-Intermediate Risk, Im…

Feat. G. Garcia-Manero
20:55
8th Eurasian Hematology Oncology Summit

2021 Lower Risk MDS Updates: RBC Transfusions, ESA in Anemia, Lenali…

Feat. M. Mittelman
13:39
8th Eurasian Hematology Oncology Summit

2021 Highlights on Higher Risk MDS: Can We Improve on Azacitidine? W…

Feat. G. Garcia-Manero
25:12
8th Eurasian Hematology Oncology Summit

2021 Updates on TFR in CML: What Are the Factors and Best Predictors…

Feat. G. Saglio
21:28
8th Eurasian Hematology Oncology Summit

How to Treat Newly Diagnosed AML in Unfit Patients: Pretreatment Tes…

Feat. T. Kadia
08:17
8th Eurasian Hematology Oncology Summit

Highlights on ETP-ALL: Recognition, Role of Allogeneic Transplant, C…

Feat. S. Chiaretti
13:48
8th Eurasian Hematology Oncology Summit

Updates on Ph-Like ALL: Genomic Background, Diagnosis, Outcomes, and…

Feat. S. Chiaretti